Last reviewed · How we verify
NCT07434388
LRFN5 and OLFM4 in Schizophrenia
trial in Schizophrenia Disorder in 60 participants. Completed in 1 December 2025.
1 December 2025
Quick facts
| Lead sponsor | Elazığ Mental Health and Diseases Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 27 April 2025 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Schizophrenia Disorder — all drugs for Schizophrenia Disorder →
Sponsor
Elazığ Mental Health and Diseases Hospital
Who can join
Adults 18 to 65, any sex, with Schizophrenia Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This cross-sectional observational study evaluated serum levels of Leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and Olfactomedin-4 (OLFM4) in patients with schizophrenia during acute exacerbation and in healthy controls. The study also assessed associations between these biomarkers and clinical symptom severity, global functioning, and systemic inflammation measured by the Aggregate Index of Systemic Inflammation (AISI). The study aimed to investigate convergent synaptic and immunoinflammatory dysregulation in schizophrenia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07434388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia Disorder
Currently open trials in the same condition.
- NCT07434479 — A Virtual Reality Mindfulness Application for Aggression in Schizophrenia · NA · recruiting
- NCT07177261 — Inter-Brain Synchrony in Schizophrenia · NA · recruiting
- NCT07309172 — KetoBrain: Brain Energy Metabolism in Schizophrenia · recruiting
Other Elazığ Mental Health and Diseases Hospital trials
Trials by the same sponsor.
- NCT07459270 — Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use · not yet recruiting
- NCT07451821 — Cognitive Disengagement Syndrome in Functional Neurological Symptom Disorder · not yet recruiting
- NCT07447960 — LRFN5 and OLFM4 in Schizoaffective Disorder · not yet recruiting
- NCT07450027 — LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis · recruiting
- NCT07444879 — IL-33, sST2, and CRP in Panic Disorder · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07434388 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Elazığ Mental Health and Diseases Hospital
- Last refreshed: 25 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07434388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing